ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴

• 資料種別: 記事
• タイトル: ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴
• 著者標目: 清木 静乃; 山下 修司; 鏑木 美帆; 玉木 啓文; 野口 義紘; 長内 理大; 伊野 陽子; 井口 和弘; 寺町 ひとみ; 林 秀樹
• 出版年月日等: 2023-02-10
• 出版年（W3CDTF）: 2023-02-10
• タイトル（掲載誌）: 医療薬学
• 巻号年月日等（掲載誌）: 49 2
• 掲載巻: 49
• 掲載号: 2
• 掲載ページ: 66-73
• 掲載年月日（W3CDTF）: 2023-02-10
• ISSN（掲載誌）: 1346342X
• ISSN-L（掲載誌）: 1346342X
• 出版事項（掲載誌）: Japanese Society of Pharmaceutical Health Care and Sciences
• 本文の言語コード: ja
• 件名標目: glucocorticoid-induced osteoporosis prevention; fracture risk factor; glucocorticoid dosage; guidelines; community pharmacists
• 対象利用者: 一般
• DOI: 10.5649/jjphcs.49.66
• 関連情報（URI）: https://www.jstage.jst.go.jp/article/jjphcs/49/2/49_66/_pdf; https://search.jamas.or.jp/link/ui/2023125958
• 参照: The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis; https://cir.nii.ac.jp/crid/1360011143651514624; Effect of frailty on quality of life in elderly patients after hip fracture: a longitudinal study; https://cir.nii.ac.jp/crid/1360016870554475776; Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan; https://cir.nii.ac.jp/crid/1360298345284507008; Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment; https://cir.nii.ac.jp/crid/1360576149766193280; Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan; https://cir.nii.ac.jp/crid/1360580935798871936; Advances in treatment of glucocorticoid-induced osteoporosis; https://cir.nii.ac.jp/crid/1361418520435653376; Excess mortality following hip fracture: the role of underlying health status; https://cir.nii.ac.jp/crid/1361981468748732928; Oral corticosteroids and fracture risk: relationship to daily and cumulative doses; https://cir.nii.ac.jp/crid/1361981468826400512; Prevalence of oral glucocorticoid usage in the United States: A general population perspective; https://cir.nii.ac.jp/crid/1361981470482967680; Glucocorticoid-induced osteoporosis: 2019 concise clinical review; https://cir.nii.ac.jp/crid/1362262944812384640; Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years; https://cir.nii.ac.jp/crid/1362544419438316672; Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004); https://cir.nii.ac.jp/crid/1363107368788409472; Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update; https://cir.nii.ac.jp/crid/1364233269595650304; Management and Treatment of Osteoporosis in Patients Receiving Long-term Glucocorticoid Treatment: Current Status of Adherence to Clinical Guidelines and Related Factors; https://cir.nii.ac.jp/crid/1390001204870579840; 骨吸収抑制薬関連顎骨壊死の最新情報; https://cir.nii.ac.jp/crid/1390001205511315968; 全国厚生連病院を対象としたステロイド性骨粗鬆症の管理に関する調査; https://cir.nii.ac.jp/crid/1390282763035010048; AORA（Akita Orthopedic Group on Rheumatoid Arthritis） registry 2017におけるステロイド性骨粗鬆症の治療現状; https://cir.nii.ac.jp/crid/1390845713086207104
• 連携機関・データベース: 国立情報学研究所 : CiNii Research
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• 要約等: <p>Glucocorticoid-induced osteoporosis (GIO) is a serious side effect of long-term glucocorticoid (GC) administration. However, sufficient high compli...